Results 31 to 40 of about 85,902 (266)

Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma.

PLoS ONE, 2019
We aimed to explore whether the combination of intradermal DNA vaccination, to boost immune response against melanoma antigens, and immune checkpoint blockade, to alleviate immunosuppression, improves antitumor effectiveness in a murine B16F10 melanoma ...
Spela Kos, Alessandra Lopes, Veronique Preat, Maja Cemazar, Ursa Lampreht Tratar, Bernard Ucakar, Kevin Vanvarenberg, Gregor Sersa, Gaelle Vandermeulen   +8 more
doaj   +1 more source

Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer

Neoplasia: An International Journal for Oncology Research, 2019
Immune checkpoint inhibitors have shown clinical benefit in several cancer entities including metastatic microsatellite instable colorectal carcinomas. However, for the majority of metastatic colorectal carcinomas the potential and limitations of immune ...
E Fiegle, D Doleschel, S Koletnik, A Rix, R Weiskirchen, E Borkham-Kamphorst, F Kiessling, W Lederle   +7 more
doaj   +1 more source

The Role of Immune Checkpoint Molecules on Macrophages in Cancer, Infection, and Autoimmune Pathologies

Frontiers in Immunology, 2022
Immune checkpoint inhibitors have revolutionized immunotherapy against various cancers over the last decade. The use of checkpoint inhibitors results in remarkable re-activation of patients’ immune system, but is also associated with significant adverse ...
Victoria C. Brom, Christof Burger, Dieter C. Wirtz, Frank A. Schildberg   +3 more
doaj   +1 more source

Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator

Acta Pharmaceutica Sinica B, 2023
The use of checkpoint-blockade antibodies is still restricted in several malignancies due to the modest efficacy, despite considerable success in anti-tumor immunotherapy.
Qingqing Xiao, Xiaotong Li, Chang Liu, Yuxin Jiang, Yonglong He, Wanting Zhang, Helena S. Azevedo, Wei Wu, Yuanzheng Xia, Wei He   +9 more
doaj   +1 more source

Immune checkpoint blockade in lymphoid malignancies [PDF]

The FEBS Journal, 2016
Malignant cells may subvert and escape endogenous host immune surveillance by up‐regulation of immune inhibitory signals known as immune checkpoints. These checkpoints are important therapeutic targets, and antibodies that block checkpoint signaling have shown remarkable efficacy in some solid tumors as well as in some refractory hematologic ...
Gita, Thanarajasingam, Uma, Thanarajasingam, Stephen M, Ansell   +2 more
openaire   +2 more sources

Photodynamic Therapy and Immune Checkpoint Blockade^† [PDF]

Photochemistry and Photobiology, 2020
AbstractImmune checkpoints including PD‐1 and CTLA‐4 help to regulate the intensity and timeframe of the immune response. Since they become upregulated in cancer and prevent sufficient antitumor immunity, monoclonal antibodies against these checkpoints have shown clinical promise for a range of cancers.
Gwendolyn M. Cramer, Edmund K. Moon, Keith A. Cengel, Theresa M. Busch   +3 more
openaire   +2 more sources

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells

Frontiers in Immunology, 2017
Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy.
Carmen Stecher, Claire Battin, Judith Leitner, Markus Zettl, Katharina Grabmeier-Pfistershammer, Christoph Höller, Gerhard J. Zlabinger, Peter Steinberger   +7 more
doaj   +1 more source

LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance

Frontiers in Oncology, 2022
Although PD-1 blockade therapy has been promising in cancer treatment, only 4% (pancreatic cancer) to 70% (melanoma) of patients have a positive response to this blockade therapy, which is one of its important disadvantages. Therefore, it is important to
Yiming Wei, Zhaoming Li
doaj   +1 more source

Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors [PDF]

Journal of Immunotherapy and Precision Oncology, 2020
A major breakthrough in cancer treatment was ushered in by the development of immune checkpoint blockade therapy such as anti-CTLA4 antibody and anti-PD-1 and anti-programmed cell death-ligand 1 antibodies that are now approved for use in an increasing ...
Kathrina L. Marcelo-Lewis, Shhyam Moorthy, Ecaterina Ileana-Dumbrava   +2 more
doaj   +1 more source

MCT4 blockade increases the efficacy of immune checkpoint blockade

Journal for ImmunoTherapy of Cancer, 2023
Background & Aims Intratumoral lactate accumulation and acidosis impair T-cell function and antitumor immunity. Interestingly, expression of the lactate transporter monocarboxylate transporter (MCT) 4, but not MCT1, turned out to be prognostic for the survival of patients with rectal cancer, indicating that ...
Babl, Nathalie, Decking, Sonja-Maria, Voll, Florian, Althammer, Michael, Sala-Hojman, Ada, Ferretti, Roberta, Korf, Clarissa, Schmidl, Christian, Schmidleithner, Lisa, Nerb, Benedikt, Matos, Carina, Koehl, Gudrun E., Siska, Peter J., Bruss, Christina, Kellermeier, Fabian, Dettmer, Katja, Oefner, Peter J., Wichland, Marvin, Ugele, Ines, Bohr, Christopher, Herr, Wolfgang, Ramaswamy, Shivapriya, Heinrich, Timo, Herhaus, Christian, Kreutz, Marina, Renner, Kathrin   +25 more
openaire   +4 more sources